Drugs / Rocbrutinib
Trials 8
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-02-25 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Regulatory HANSOH PHARMA RECEIVED APPROVAL FROM NMPA FOR CLINICAL TRIAL OF HS-10561, A SMALL MOLECULE BTK INHIBITOR FOR CHRONIC SPONTANEOUS URTICARIA hspharm.com ↗
HS-10561 capsules, which is jointly developed by the Group and in collaboration with Guangzhou Lupeng Pharmaceutical Co., Ltd. * (廣州麓鵬製藥有限公司), has obtained clinical trial approval by the National Medical Products Administration (NMPA) of China |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-02-25 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | HANSOH PHARMA RECEIVED APPROVAL FROM NMPA FOR CLINICAL TRIAL OF HS-10561, A SMALL MOLECULE BTK INHIBITOR FOR CHRONIC SPONTANEOUS URTICARIA hspharm.com ↗ |
| 2024-08-08 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | HANSOH PHARMA AND LUPENG PHARMA ANNOUNCE LICENSING AGREEMENT FOR LP-168 hspharm.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rocbrutinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07342478 ↗ |
| Known as | LP-168 | “Rocbrutinib (LP-168) is a novel, highly selective, fourth-generation Bruton's tyrosine kinase (BTK) inhibitor” NCT07377578 ↗1“Rocbrutinib (LP-168) is a selective next-generation inhibitor of BTK” NCT07342478 ↗ |
| Action | Inhibit | “new generation Bruton Tyrosine Kinase inhibitor Rocbrutinib” NCT06251180 ↗ |
| Modality | Small molecule | — CHEMBL5314539 ↗ |
| Route | Oral | “Rocbrutinib tablets orally” NCT05716087 ↗ |
| Target | BTK | “new generation Bruton Tyrosine Kinase inhibitor Rocbrutinib” NCT06251180 ↗ |